以北京市垂杨柳医院2017年5月至2020年5月收治的50例糖尿病DKA患者为研究对象，分为赖脯组和门冬组（n=25），赖脯组使用重组赖脯胰岛素，门冬组使用门冬胰岛素。结果显示，两组的血糖达标时间、不良反应发生情况无统计学差异（P>0.05）；赖脯组患者空腹血糖、餐后2 h血糖水平低于门冬组，且尿酮体转阴时间、pH值恢复时间短于门冬组。说明赖脯胰岛素治疗DKA具有一定的优势，其控制血糖、纠正DKA的速度更快，效果更好。
In this study, 50 DKA patients admitted in our hospital from May 2017 to May 2020 are included as the subjectsin this study, and they are divided into the Insulin Lispro group and the Insulin Aspart group. It is shown that there is no significant difference in the recovering time of the blood glucose, and the complication rates between the two groups (P>0.05); in the Lispro group, the fasting blood glucose and the postprandial 2 h blood glucose levels are lower than those in the Aspart group, and the recovery times of the negative urinary ketone and the bloody pH value are shorter than those in the Aspart group. It is suggested that the insulin Lispro has certain advantages in the treatment of the DKA, with higher speeds of controlling the blood glucose and correcting the DKA.
[1] Saeedi P, Petersohn I, Salpea P, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045:Results from the International Diabetes Federation Diabetes Atlas, 9th edition[J]. Diabetes Research and Clinical Practice, 2019, 157:107843.
[2] 贾伟平. 2018年我国糖尿病防治进展[J].中华医学信息导报, 2018, 33(24):14.
[3] 刘叶青,芦晶晶,周亚茹.糖尿病大血管病变的综合管理进展[J].中国医刊, 2018, 53(4):355-358.
[4] 邢小燕.努力提高糖尿病血管并发症的防治水平[J].中国医刊, 2018, 53(4):349-350.
[5] Garrett C J, Choudhary P, Amiel S A, et al. Recurrent diabetic ketoacidosis and a brief history of brittle diabetes research:Contemporary and past evidence in diabetic ketoacidosis research including mortality, mental health and prevention[J]. Diabetic Medicine, 2019, 36(11):1329-1335.
[6] Shen H, Zhu W K, Lu Z, et al. Hotspot analysis of traditional drugs in diabetes treatment literature[J].中国结合医学杂志(英文版), 2021, 27(4):304-312.
[7] 魏瑾然.大柴胡汤保留灌肠联合胰岛素泵治疗对糖尿病酮症酸中毒并发急性胰腺炎的疗效观察[J].中国临床医生杂志, 2018, 46(9):1120-1122.
[8] 马宇航,彭永德. 2型糖尿病降糖药物治疗进展[J].中国临床保健杂志, 2020, 23(4):437-445.
[9] 中华医学会糖尿病学分会.中国2型糖尿病防治指南(2017年版)[J].中国实用内科杂志, 2018, 38(4):292-344.
[10] 蒋景敏.糖尿病酮症酸中毒的研究进展[J].家庭医药,就医选药, 2018(6):92-93.
[11] Yang X B, Deng H R, Zhang X Z, et al. Insulin requirement profiles and related factors of insulin pump therapy in patients with type 2 diabetes[J]. Science China (Life Sciences), 2019, 62(11):96-103.
[12] 李军.胰岛素联合中医药急救治疗糖尿病酮症酸中毒的可行性及安全性[J].四川中医, 2018, 36(2):102-104.
[13] 周瑾,纪立伟.不同种类餐时胰岛素联合基础胰岛素方案治疗2型糖尿病的成本-效果分析[J].中国医院用药评价与分析, 2020, 20(5):580-582.
[14] 刘春英,刘彩霞.采用胰岛素泵治疗2型糖尿病的疗效及对患者生活质量的影响[J].中国基层医药, 2015, 22(3):419-421.
[15] 李素娟.胰岛素泵的工作原理[J].解放军健康, 2010(5):18.
[16] Alderisio A, Bozzetto L, Franco L, et al. Long-term body weight trajectories and metabolic control in type 1 diabetes patients on insulin pump or multiple daily injections:A 10-year retrospective controlled study[J]. Nutrition, Metabolism and Cardiovascular Diseases, 2019, 29(10):1110-1117.
[17] 孔令兰.胰岛素泵治疗新诊断2型糖尿病患者42例疗效分析[J].贵州医药, 2016, 40(6):640-642.
[18] 黄葶,崔巍.长期带胰岛素泵与不带泵2型糖尿病患者抑郁与生活质量比较[J].中华现代护理杂志, 2020, 26(23):3222-3225.
[19] 张筠,路素丽,王建平.微量白蛋白尿期2型DKA患者使用胰岛素泵治疗的疗效观察与分析[J].基因组学与应用生物学, 2018, 37(11):4943-4948.
[20] Evans M, Ceriello A, Danne T, et al. Use of fast-acting insulin aspart in insulin pump therapy in clinical practice[J]. Wiley-Blackwell Online Open, 2019, 21(9):2039-2047.
[21] Zijlstra E, Demissie M, Graungaard T, et al. Investigation of pump compatibility of fast-acting insulin aspart in subjects with type 1 diabetes[J]. Journal of Diabetes Science and Technology, 2018, 12(1):145-151.
[22] 张嵩,陈宽,闵栋,等.发展数字生态系统,提升糖尿病管理水平[J].中国医刊, 2020, 55(6):3.
